For Immediate Release

Chicago, IL - March 27, 2009 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Baker Hughes, Inc. (BHI), International Business Machines Corp. (IBM), China Mobile Ltd. ADS (CHL), Neurocrine Biosciences, Inc. (NBIX) and Potash Corp. (POT).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=4579.

Here are highlights from Thursday's Analyst Blog:

Baker-Hughes a Buy Up to $50

Our continued favorable view of Baker Hughes, Inc. (BHI) shares reflects the company's limited exposure to the weak North American natural gas market, its leading product-centric asset portfolio with a strong international

...

Lilac Petal Results Lie in the Interpretation of the DataOn March 25, 2009, Neurocrine Biosciences, Inc. (NBIX) reported results from the phase II -702 study, also called Lilac Petal, testing elagolix for the treatment of endometriosis.Elagolix met the primary efficacy goal for both the 150mg and 250mg on the clinically validated PGI-C scale for both overall lower PGI-C score and percent of women with a score below 2. The 150mg dose was also statistically significant for the clinically validated EHP scale.Management was also able to show a statistically significant reduction in baseline for the NRS-peak scale and dysmenorrhea (DYS).  The trial failed to show a significant reduction in NMPP or the NRS-mean scale, both which management hypothesized where measuring the same thing -- non-menstrual pelvic pain on a daily basis -- to a correlation of 0.9, and both which started with baseline ...